The MonALISA (Monitoring Agents in a Large Integrated Services Architecture) framework provides a set of distributed services for monitoring, control, management and global optimization for large ...scale distributed systems. It is based on an ensemble of autonomous, multi-threaded, agent-based subsystems which are registered as dynamic services. They can be automatically discovered and used by other services or clients. The distributed agents can collaborate and cooperate in performing a wide range of management, control and global optimization tasks using real time monitoring information.
Program title: MonALISA
Catalogue identifier: AEEZ_v1_0
Program summary URL:
http://cpc.cs.qub.ac.uk/summaries/AEEZ_v1_0.html
Program obtainable from: CPC Program Library, Queen's University, Belfast, N. Ireland
Licensing provisions: Caltech License – free for all non-commercial activities
No. of lines in distributed program, including test data, etc.: 147 802
No. of bytes in distributed program, including test data, etc.: 2 5913 689
Distribution format: tar.gz
Programming language: Java, additional APIs available in Java, C, C++, Perl and python
Computer: Computing Clusters, Network Devices, Storage Systems, Large scale data intensive applications
Operating system: The MonALISA service is mainly used in Linux, the MonALISA client runs on all major platforms (Windows, Linux, Solaris, MacOS).
Has the code been vectorized or parallelized?: It is a multithreaded application. It will efficiently use all the available processors.
RAM: for the MonALISA service the minimum required memory is 64 MB; if the JVM is started allocating more memory this will be used for internal caching. The MonALISA client requires typically 256–512 MB of memory.
Classification: 6.5
External routines: Requires Java: JRE or JDK to run. These external packages are used (they are included in the distribution): JINI, JFreeChart, PostgreSQL (optional).
Nature of problem: To monitor and control distributed computing clusters and grids, the network infrastructure, the storage systems, and the applications used on such facilities. The monitoring information gathered is used for developing the required higher level services, the components that provide decision support and some degree of automated decisions and for maintaining and optimizing workflow in large scale distributed systems.
Solution method: The MonALISA framework is designed as an ensemble of autonomous self-describing agent-based subsystems which are registered as dynamic services. These services are able to collaborate and cooperate in performing a wide range of distributed information-gathering and processing tasks.
Running time: MonALISA services are designed to run continuously to collect monitoring data and to trigger alarms or to take automatic actions in case it is necessary.
References:
1
http://monalisa.caltech.edu.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
The aim of this cross-sectional study was to identify the major factors influencing pulmonary function in CF patients from western side of Romania.
The study enrolled 51 patients with CF between the ...ages of 6 and 27.8 years who were monitored at regular visits to the National Cystic Fibrosis Centre and Pius Branzeu County Hospital in Timisoara, Romania, over a period of 2 years. The relationships between lung function, as measured by forced expiratory volume in 1 s (FEV
), with patient age, sex, body mass index (BMI), pancreatic insufficiency (PI), microbial infection, CF-related diabetes (CFRD), CF-associated liver disease (CFLD), and physical activity <30 min/day, were evaluated by multivariate regression analysis.
The results showed that FEV1 was 0.32% higher for each increase in percentile of BMI (95% confidence interval: 0.034-0.619). In addition, mean FEV
was 1.52% lower with every year rise of age. PI and female sex increased the risk of impaired lung function (FEV
<60%). The factors most closely correlated with pulmonary function in pediatric CF patients were current age (negative) and BMI (positive).
The findings of this study, in combination with what is known from other studies in CF, suggest that a better nutritional status and infection prophylaxis should be part of a comprehensive clinical management strategy for pediatric CF in Romania.
Highlights • Compared advanced NSCLC phase III trials: pemetrexed–cisplatin with or without pem maintenance. • 4 cycles pem–cis followed by pem maintenance improves survival over 6 cycles pem–cis. • ...Longer exposure to pem–cis or maintenance pem increases some toxicities, but overall incidence low.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UL, UM, UPCLJ, UPUK
Hypertension (HTN), a recognized adverse effect of angiogenesis inhibitors, may be a potential biomarker of activity of these agents. We conducted a retrospective analysis to examine the incidence ...and predictors of the development of on-treatment HTN with the vascular endothelial growth factor receptor tyrosine kinase inhibitor cediranib, and the relationship of this adverse event with treatment outcomes.
BR24 was a double-blind placebo-controlled phase II trial of carboplatin/paclitaxel chemotherapy with either daily oral cediranib or placebo in patients (n = 296) with advanced non-small-cell lung cancer (NSCLC). Exploratory analyses characterized relationships between HTN, baseline variables, and efficacy outcomes.
New onset or worsening of preexisting HTN (treatment-emergent HTN) was more frequent in patients receiving cediranib (68 versus 45%, P < 0.0001). Factors associated with HTN in all randomized patients were good performance status and treatment with cediranib. In both arms, treatment-emergent HTN was associated with improved efficacy outcomes, but there was no evidence of a differential treatment effect, with nonsignificant interaction P values.
In advanced NSCLC, HTN is frequent in patients receiving chemotherapy, with or without cediranib. The development of HTN was favorably prognostic in these patients, but not predictive of a differential outcome with cediranib.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
The majority of patients with non-small cell lung (NSCLC) present with advanced, metastatic disease at the time of diagnosis. The current state of the art for the management of this condition is ...first- and second-line chemotherapy (CT), along with appropriate supporting care measures, which are supposed to alleviate symptoms and to improve survival. During the last years, maintenance therapy (MT) was included in the therapeutic algorithm for these patients. MT could be defined as continuation of an active treatment until disease progression in patients who demonstrated a non-progressing status following induction chemotherapy. Despite the results of several randomized trials showing a significant benefit by using this approach, the strategy is far from being universally accepted. The internationally recognized guidelines provide different recommendation when it comes to this topic, while some major drawbacks in the design of the positive clinical trials may have distorted the relevance of the communicated data. This paper aimed to review the most contentious aspects which should be considered while contemplating the use of MT in the daily clinical practice.
My personal highlights of ESMO 2016 Dediu, M.; Gerger, A.; Zojer, N. ...
Memo - Magazine of European medical oncology,
2017/2, Volume:
10, Issue:
1
Journal Article
Peer reviewed
Open access
Summary
Results of several clinically relevant studies were presented at the 2016 Annual Meeting of the European Society of Medical Oncology (ESMO). This article summerizes the personal highlights of ...three medical oncologists in their respective areas of expertise.
Full text
Available for:
EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OBVAL, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
Background: Casopitant mesylate is a novel, oral neurokinin-1 receptor antagonist with demonstrated antiemetic efficacy. We conducted a randomized, double-blind, controlled phase II trial to evaluate ...three casopitant doses as part of a triple-therapy regimen for the prevention of nausea and vomiting associated with high-dose cisplatin. The aim of the study was to detect a dose response. Patients and methods: A total of 493 patients with solid tumors receiving a first cycle of cisplatin ≥70 mg/m2 were randomly assigned among six treatment arms. The primary analysis compared a control arm ondansetron/dexamethasone (Ond/Dex) with three investigational treatments (Ond/Dex plus oral casopitant 50, 100, or 150 mg administered daily for 3 days). Two exploratory arms were included: one evaluating a single oral casopitant dose of 150 mg added to standard Ond/Dex and another with 3-day oral aprepitant-based therapy (Ond/Dex plus aprepitant 125 mg day 1, 80 mg days 2–3). Results: The complete response (CR) rate (defined as no vomiting, retching, rescue therapy, or premature discontinuation) was significantly increased in each casopitant arm relative to control over the 120-h evaluation period: 76% (50 mg), 86% (100 mg), 77% (150 mg), and 60% with control (P = 0.0036). The CR rate for the single oral dose regimen was similar to the CR rate reported for the 3-day regimens. No differences were observed in the incidence of nausea or significant nausea among groups in the primary analysis. The most common adverse events related to treatment included headache (n = 10) and hiccups (n = 14). Conclusion: All doses of oral casopitant as a 3-day regimen (and likely as a 150-mg single oral dose) in combination with Ond/Dex provided significant improvement in the prevention of cisplatin-induced emesis.
Full text
Available for:
GEOZS, IJS, IMTLJ, KILJ, KISLJ, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, UILJ, UL, UM, UPCLJ, UPUK, ZAGLJ, ZRSKP
This paper summarizes evidence of a nonlinear frequency dependence of attenuation for compressional waves in shallow-water waveguides with sandy sediment bottoms. Sediment attenuation is found ...consistent with alpha(f) = alpha(f(o)) x (f/f(o))n, n approximately 1.8 +/- 0.2 at frequencies less than 1 kHz in agreement with the theoretical expectation, (n = 2), of Biot J. Acoust. Soc. Am. 28(2), 168-178, 1956. For frequencies less than 10 kHz, the sediment layers, within meters of the water-sediment interface, appear to play a role in the attenuation that strongly depends on the power law. The accurate calculation of sound transmission in a shallow-water waveguide requires the depth-dependent sound speed, density, and frequency-dependent attenuation.
PDF
